NCT02997163View on ClinicalTrials.gov

An Open-Label Pharmacokinetics and Safety Study of Talazoparib

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

February 21, 2017

Primary Completion Date

January 30, 2019

Study Completion Date

January 30, 2019

Conditions
Advanced Solid Tumors
Interventions
DRUG

Talazoparib

Daily oral doses of talazoparib 0.5 mg

Trial Locations (10)

46804

Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne

46845

Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne

48201

Karmanos Cancer Institute, Detroit

48334

Karmanos Cancer Institute Weisberg Cancer Treatment Center, Farmington Hills

77030

The University of Texas MD Anderson Cancer Center, Houston

08901

Robert Wood Johnson University Hospital, New Brunswick

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

T6G 1Z2

Cross Cancer Institute, Edmonton

L8V 5C2

Juravinski Cancer Centre, Hamilton

H3T 1E2

Jewish General Hospital, Montreal

Sponsors

Lead Sponsor

Pfizer

Collaborators (1)

Medivation, Inc.
All Listed Sponsors
collaborator

Medivation, Inc.

INDUSTRY

lead

Pfizer

INDUSTRY

NCT02997163 - An Open-Label Pharmacokinetics and Safety Study of Talazoparib | Biotech Hunter | Biotech Hunter